17 recruiting, 10 active not recruiting, 10 completed, 6 not yet recruiting. 32 Phase 1, 23 Phase 2, 3 Early Phase 1.
Follow B-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of B-Cell Non-Hodgkin Lymphoma trials Research Report on B-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INfections in Patients Treated With CAR-T Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 290 | 2026-11-01 | 2026-07-20 | |
| A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma SHR-3079 Injection - B-cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 90 | 2026-07-23 | 2026-08-07 |
| A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma HP-002 - B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Helioson Pharmaceutical Co., Ltd. | 114 | 2026-06-26 | 2026-06-22 |
| Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma GI001 Injection - B-Cell Non-Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Ruijin Hospital | 9 | 2026-04-20 | 2026-05-13 |
| A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies DS3790a, Combination drug - Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 420 | 2026-01-16 | 2026-08-24 |
| Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2026-01-01 | 2026-03-18 | |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia GI001 - B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Hematology department of the 920th hospital | 18 | 2025-11-28 | 2026-10-07 |
| A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma AZD4512 - B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 91 | 2025-09-24 | 2026-10-14 |
| A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma CAR-T cells chimenric antigen receptor T cells - B-Cell Non-Hodgkin Lymphoma | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2025-07-15 | 2025-07-16 |
| A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) CAR T cells - B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Tongji Hospital | 27 | 2025-07-09 | 2025-11-17 |
| A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 ) CAR T cells - B-Cell Non-Hodgkin Lymphoma | Phase 1 | Not yet recruiting | Qian Wenbin | 27 | 2025-07-08 | 2025-06-23 |
| JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma JWCAR239, Fludarabine, Cyclophosphamide - B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma | Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2025-07-01 | 2025-06-17 |
| A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) ABO2203 Injection - B-cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Ruijin Hospital | 56 | 2025-05-26 | 2025-07-18 |
| Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy) - B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Kansas Medical Center | 54 | 2025-03-31 | 2026-05-14 |
| A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma CAR T cells - B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Kai Hu | 24 | 2025-02-10 | 2025-02-12 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-10-28 |
| A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma CAR T cells - B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Aibin Liang，MD，Ph.D. | 24 | 2024-12-30 | 2025-01-03 |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL Surovatamig - B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL) | Phase 2 | Recruiting | AstraZeneca | 270 | 2024-11-27 | 2026-10-14 |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Biospecimen Collection, Computed Tomography, Echocardiography - B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 11 | 2024-09-30 | 2026-09-14 |
Showing 20 of 52. Sign in to see all of them.
Lymphoma, B-Cell (52) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Leukemia, Myeloid, Acute (7) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, T-Cell (7) · Multiple Myeloma (6) · Myelodysplastic Syndromes (6) · Recurrence (5) · Burkitt Lymphoma (4) · Hematologic Neoplasms (4) · Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4)
Hemic and Lymphatic Diseases (52) · Immune System Diseases (52) · Immunoproliferative Disorders (52) · Lymphatic Diseases (52) · Lymphoproliferative Disorders (52) · Neoplasms by Histologic Type (52) · Neoplasms (50) · Lymphoma (48) · Lymphoma, Non-Hodgkin (45) · Hematologic Diseases (15) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Disease Attributes (12) · Leukemia (12) · Leukemia, Lymphoid (10)
Cyclophosphamide (12) · Rituximab (8) · Doxorubicin (7) · Prednisone (7) · Vincristine (6) · Immunotherapy, Adoptive (5) · Magnetic Resonance Spectroscopy (5) · Specimen Handling (4) · Biopsy (3) · CT-P10 (3) · deltacortene (3) · fludarabine (3) · polatuzumab vedotin (3) · prednylidene (3) · Etoposide (2)
AstraZeneca (4) · Fred Hutchinson Cancer Center (3) · Alopexx Oncology, LLC (2) · City of Hope Medical Center (2) · Hoffmann-La Roche (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Mayo Clinic (2) · Northwestern University (2) · Ruijin Hospital (2) · University of Washington (2) · ADC Therapeutics S.A. (1) · Aibin Liang，MD，Ph.D. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Children's Oncology Group (1) · Daiichi Sankyo (1)
United States (32) · China (19) · Italy (7) · Spain (6) · United Kingdom (6) · Australia (4) · France (4) · Japan (4) · South Korea (4) · Taiwan (4) · Canada (3) · Germany (3) · Belgium (2) · Czechia (2) · Denmark (2)
Daniel Vlock, MD (2) · Reem Karmali, MD (2) · Aibin Liang MD,Ph.D. (1) · Ajay Gopal (1) · Alex Herrera (1) · Andrew S Artz (1) · Anita Kumar, MD (1) · Ching-Liang Ho, MD (1) · Daniel Hommes (1) · Daobin Zhou (1) · David Garcia (1) · Debra Wood, MD (1) · Issa Khouri (1)
PMID 29246938, PMID 30901302, PMID 31699827, PMID 34362494, PMID 34530933, PMID 34780125, PMID 35135810, PMID 35175355, PMID 35973200, PMID 36898933, PMID 37581593, PMID 38072960, PMID 39908481, PMID 40706069, PMID 42013019, PMID 42283231
2018 (2), P30CA015704 (2), P30CA033572 (2), P30CA060553 (2), 2023 (1), 2025 (1), P01CA049605 (1), P30CA012197 (1), P50CA107399 (1), P50CA186781 (1), R01CA262613 (1), R35CA197353 (1), UG1CA189955 (1)